Companies › NeuroRx
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NRX-101 D-cycloserine (NMDA co-agonist/glycine site modulator) + Lurasidone (5-HT and dopamine ant | GLRA1, HTR2A | Phase 2 | Treatment Resistant Depression | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07227103 | NRX-101 | Phase 2 | Treatment Resistant Depression | Psychiatry | Dec 2027 |
Cybin IRL Bazelet Nehushtan Autobahn Therapeutics atai Therapeutics Arialys Australia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.